Targeted Leukemia Treatments Report

$3,850.00

New treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of Leukemias and related blood cancers. This report examines two dozen therapeutic drugs targeting Leukemias, and their mechanisms of action.

Category:

Description

Over the last two decades, targeted therapies have also become part of the standard of care for some types of leukemia. Different types of leukemia require different combinations of therapies. Although much progress has been made against some types of leukemia, others still have relatively poor rates of survival. And, as the population ages, there is a greater need for treatment regimens that are less toxic. CAR T-cell therapy has recently generated great excitement for the treatment of children with relapsed ALL. One CAR T-cell therapy, tisagenlecleucel (Kymriah), was approved in 2017 for some children with relapsed ALL.